Things to consider. Labs with kiestra would never consider adding an APAS module as they would not be compatible in the workflow. Kiestra is already a TOTAL lab solution. Labs with the scale to justify a kiestra system need to be very large. This equipment is custom designed per lab. Also outlay is in the millions. APAS will target small to medium labs and should be much cheaper to purchase.
Still shame tech wont be added bd lineup. Although if its superior and fda approved its not too late for a new deal.
Why the hype?, page-86
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.001(6.25%) |
Mkt cap ! $23.30M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.5¢ | $8.549K | 565.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 188838 | 1 |
View Market Depth
| Last trade - 11.33am 09/07/2024 (20 minute delay) ? |
| LBT (ASX) Chart |